PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32115500-0 2020 Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer. Docetaxel 0-9 high mobility group box 1 Homo sapiens 22-27 34914264-1 2021 Objective: To investigate the effect of silencing the high-mobility group box-1 protein (HMGB1) combined with docetaxel (DTX) on the proliferation and apoptosis of PCa cells and its possible action mechanism. Docetaxel 121-124 high mobility group box 1 Homo sapiens 54-79 34914264-10 2021 The expression of the HMGB1 protein was markedly lower in the si-HMGB1+DTX than in the DTX group (P < 0.05). Docetaxel 87-90 high mobility group box 1 Homo sapiens 22-27 34914264-11 2021 CONCLUSIONS: Silencing HMGB1 combined with DTX chemotherapy can inhibit the proliferation and promote the apoptosis of PCa cells, which may be attributed to its regulatory effect on the expressions of the Bcl-2 family-related proteins. Docetaxel 43-46 high mobility group box 1 Homo sapiens 23-28 32115500-6 2020 On the other hand, plasma levels of high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) protein, showed significant increase after docetaxel treatment. Docetaxel 159-168 high mobility group box 1 Homo sapiens 36-61 32115500-6 2020 On the other hand, plasma levels of high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) protein, showed significant increase after docetaxel treatment. Docetaxel 159-168 high mobility group box 1 Homo sapiens 63-68 32115500-9 2020 These findings imply that docetaxel could be involved in anti-tumor immunity via HMGB1. Docetaxel 26-35 high mobility group box 1 Homo sapiens 81-86 30744691-0 2019 Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. Docetaxel 71-80 high mobility group box 1 Homo sapiens 100-105 30744691-4 2019 Functional experiments were carried out to check whether docetaxel (DOC), a chemotherapeutic agent, modifies the expression of HMGB1 and CXCL11, and influences the infiltration properties of CD8+ T cells to the tumor microenvironment. Docetaxel 57-66 high mobility group box 1 Homo sapiens 127-132 30744691-4 2019 Functional experiments were carried out to check whether docetaxel (DOC), a chemotherapeutic agent, modifies the expression of HMGB1 and CXCL11, and influences the infiltration properties of CD8+ T cells to the tumor microenvironment. Docetaxel 68-71 high mobility group box 1 Homo sapiens 127-132 30744691-8 2019 DOC treatment significantly increased HMGB1 release in an ROS-dependent manner. Docetaxel 0-3 high mobility group box 1 Homo sapiens 38-43 30744691-12 2019 CONCLUSIONS: Our results demonstrate that DOC induces CD8+ T cell recruitment to the tumor microenvironment by enhancing the secretion of HMGB1 and CXCL11, thus improving the anti-tumor efficacy, indicating that modulating the HMGB1-CXCL11 axis might be helpful for NSCLC treatment. Docetaxel 42-45 high mobility group box 1 Homo sapiens 138-143 30744691-12 2019 CONCLUSIONS: Our results demonstrate that DOC induces CD8+ T cell recruitment to the tumor microenvironment by enhancing the secretion of HMGB1 and CXCL11, thus improving the anti-tumor efficacy, indicating that modulating the HMGB1-CXCL11 axis might be helpful for NSCLC treatment. Docetaxel 42-45 high mobility group box 1 Homo sapiens 227-232 24996221-0 2014 HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Docetaxel 34-43 high mobility group box 1 Homo sapiens 0-5 27457217-3 2016 We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high-mobility group box 1 protein (HMGB1) in the circulation. Docetaxel 38-47 high mobility group box 1 Homo sapiens 112-137 27457217-3 2016 We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high-mobility group box 1 protein (HMGB1) in the circulation. Docetaxel 38-47 high mobility group box 1 Homo sapiens 147-152 26469759-5 2015 Supernatants from DTX-treated DU145 tumor cells, which were shown to contain HMGB1, effectively induced sCLU from newly-plated DU145 tumor cells and protected them from DTX toxicity. Docetaxel 18-21 high mobility group box 1 Homo sapiens 77-82 26469759-5 2015 Supernatants from DTX-treated DU145 tumor cells, which were shown to contain HMGB1, effectively induced sCLU from newly-plated DU145 tumor cells and protected them from DTX toxicity. Docetaxel 169-172 high mobility group box 1 Homo sapiens 77-82 24996221-8 2014 RESULTS: HMGB1 translocated from the nucleus to the cytoplasm in LAD cells exposed to docetaxel and acted as a positive regulator of autophagy, which inhibited apoptosis and increased drug resistance. Docetaxel 86-95 high mobility group box 1 Homo sapiens 9-14 24996221-9 2014 Suppression of HMGB1 restored the sensitivity of LAD cells to docetaxel both in vivo and in vitro. Docetaxel 62-71 high mobility group box 1 Homo sapiens 15-20 24996221-11 2014 CONCLUSIONS: Our results demonstrated that HMGB1-regulated autophagy is a significant contributor to docetaxel resistance in LAD cells. Docetaxel 101-110 high mobility group box 1 Homo sapiens 43-48 24996221-12 2014 Suppression of HMGB1 or limiting HMGB1 cytosolic translocation diminished autophagic protection in response to docetaxel in LAD cells. Docetaxel 111-120 high mobility group box 1 Homo sapiens 15-20 24996221-12 2014 Suppression of HMGB1 or limiting HMGB1 cytosolic translocation diminished autophagic protection in response to docetaxel in LAD cells. Docetaxel 111-120 high mobility group box 1 Homo sapiens 33-38 23019417-0 2012 Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Docetaxel 13-22 high mobility group box 1 Homo sapiens 73-78 23410002-6 2013 RESULTS: Treatment of HCC1143 cells with epirubicin/docetaxel resulted in a significant HMGB-1 release in vitro. Docetaxel 52-61 high mobility group box 1 Homo sapiens 88-94 23410002-0 2013 Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Docetaxel 51-60 high mobility group box 1 Homo sapiens 7-13 23410002-3 2013 We hypothesized that the initial dose of NCT with epirubicin/docetaxel induces changes in plasma HMGB-1 which could allow for an early prediction of response to therapy. Docetaxel 61-70 high mobility group box 1 Homo sapiens 97-103 23410002-4 2013 MATERIALS AND METHODS: First, we analysed whether epirubicin/docetaxel releases HMGB-1 from HCC1143 breast cancer cells in vitro. Docetaxel 61-70 high mobility group box 1 Homo sapiens 80-86